Basic Info.
| Model NO. |
Sodium Chloride Injection |
Pharmaceutical Technology |
Chemical Synthesis |
| Transport Package |
24~30bottles/Carton |
Specification |
500ml |
| Trademark |
SHIMEN |
Production Capacity |
1 Billion / Year |
Product Description
| Model NO. |
50ml/100m/200ml/250ml/400ml/500ml |
Ingredient
|
Sodium Chloride |
| Standard 1 |
BP |
Transport Package |
PP Bottles in Carton |
| Standard 2 |
USP |
Production Capacity |
10 Million Bottles/Year |
| Origin |
P. R. China |
|
|
Detailed Photos
Company Profile
The ceaseless struggle has led to repeated achievements. Successively, three new products were approved each day, and the R&D innovation record of Shijiazhuang Siyao Group continued to be "refreshed".
On May 30, the peritoneal dialysate (lactate -G4.25%, 2000ml) and acetaminophen mannitol injection (50ml:500mg) developed by Shijiazhuang Sipharmaceutical Group obtained the registration approval of the State Food and Drug Administration, and passed or deemed to have passed the consistency evaluation. Among them, acetaminophen mannitol injection (50ml:500mg) was the second domestic approval. At the same time, the group's Hebei Guolong Pharmaceutical Co., Ltd. declared triagliptin succinate has also been approved by the State Food and Drug Administration and registered as a raw material for use in listed preparations.
It is understood that peritoneal dialysate (lactate-G4.25%) is mainly used for chronic renal failure patients who need continuous ambulatory-free peritoneal dialysis treatment because non-dialysis treatment has failed. At present, a total of 5 specifications of peritoneal dialysate and low-calcium peritoneal dialysate of the group have been approved through consistency evaluation, which can better meet different clinical needs. Acetaminophen mannitol injection is indicated for the relief of fever in adults. Triagliptin succinate is an oral, long-acting anti-type 2 diabetes drug.
In the past two years, Shijiazhuang Siyao Group system standard, around the anti-infection, respiratory system, nervous system, cardiovascular and cerebrovascular, digestion, anesthesia, endocrine and anti-tumor, dialysis and other key areas of research and development, continue to promote the integrated development of "apis + preparations", product iteration and innovation, accumulated, showing a full of flowers, fruitful situation. Since the beginning of this year, 37 new product approvals have been obtained, and a total of 85 varieties and 116 products have passed or been regarded as passing the consistency evaluation, and the continuous landing of innovation achievements has empowered enterprises to move up the value chain to the middle and high-end.
Audited Supplier 
){kind=link}